story of the week
Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients With Previously Treated HR+/HER2+ Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Safety and efficacy of tucatinib, letrozole and palbociclib in patients with previously treated HR+/HER2+ breast cancer
Clin. Cancer Res 2023 Jun 26;[EPub Ahead of Print], E Shagisultanova, W Gradishar, U Brown-Glabberman, P Chalasani, AJ Brenner, A Stopeck, H Parris, D Gao, T Mcspadden, J Mayordomo, JR Diamond, P Kabos, VF BorgesFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.